PEB - Pacific Edge Ltd

**FrankF** · 10-11-2022, 12:13 PM

Thanks Defater for let us know about this sad news.
As a junior member of this forum, I do appreciate the insightful ideas shared by a number of experts/contributors, and Miner is one of these kind people.
Condolences to his family and friends.

**Mel** · 16-11-2022, 01:03 PM

Upward movement, with $0.50 being breached, not aware of any news aside from results announcement next Thursday.

**Sideshow Bob** · 24-11-2022, 08:44 AM

https://www.nzx.com/announcements/402943

FINANCIAL RESULTS FOR THE HALF YEAR TO 30 SEPTEMBER 2022
PACIFIC EDGE INVESTMENT FOR GROWTH DELIVERS EARLY RESULTS
HIGHLIGHTS
• Operating revenue from test sales increases 62% to $8.7 million when compared to the same period of the prior year (1H22); total revenue increases 102% to $13.6 million when compared with 1H22, with increases from commercial test volume growth boosted by foreign exchange gains
• Total laboratory throughput rises 34% to 14,917 in line with analyst expectations, lifted by a 35% increase in commercial test volumes to 12,422, with growth led by the US market
• Investments driving Cxbladder adoption and lifting US clinician engagement; staff numbers increase from 86 at the end of March 2022 to 100 full-time-equivalents (FTE) at 30 September 2022
• Kaiser Permanente using Cxbladder Triage at 11 sites, two of which are in the Top 20 sites by volume during 1H23
• Net losses after tax increased to $10.6 million, from $9.0 million in 1H22 as Pacific Edge continues to invest for growth
• Cash, cash equivalents and short-term deposits of $93.5 million as at 30 September 2022, down from $105.4 million at 31 March 2022, provides strong foundation for continued investment
• Optimistic outlook tempered by proposed LCD from Novitas and the potential to affect Medicare reimbursement.

**winner69** · 24-11-2022, 09:01 AM

Out of a morbid fascination of this company I looked at the Balance Sheet

Accumulated Losses rolled over the $200m mark

Another milestone met?

**psychic** · 24-11-2022, 09:28 AM

I like to keep an eye on NZ test sales. Insignificant in the overall scheme of things but given the tests are apparently in the clinical pathway here, I'd have thought a reasonable yardstick for future US growth. NZ test sales down 30%. All a bit queer.
100 sales staff on the ground in the US eh, becoming quite an operation. So much resting on the CMS review...

**850man** · 24-11-2022, 10:59 AM

and on the KP EMR integration which in itself will be a big step forwards. Results preso about to start for those interested

**Brain** · 24-11-2022, 05:32 PM

Originally Posted by psychic

I like to keep an eye on NZ test sales. Insignificant in the overall scheme of things but given the tests are apparently in the clinical pathway here, I'd have thought a reasonable yardstick for future US growth. NZ test sales down 30%. All a bit queer.
100 sales staff on the ground in the US eh, becoming quite an operation. So much resting on the CMS review...

I would like to know where you saw that because all I can find is

”In the Asia Pacific, where test numbers are dominated by the relatively mature New Zealand market, total laboratory throughput volumes were flat versus the same period a year ago at 2,148 tests. Commercial test volumes increased 5% to 1,800 tests.”